Clinical Trials - April 20, 2015
Active Biotech Shares Plunge
Shares of Ipsen and partner Active Biotech plunged last week after Ipsen’s experimental prostate cancer drug Tasquinimod failed during a Phase III trial. Active’s shares dropped 60 percent and Ipsen’s went down by 10 percent. “The data at hand is unambiguous and cannot motivate further development of tasquinimod in this patient population,” said Tomas Leanderson, […]
